- Investing Ideas
- U.S. Pharmaceuticals & Biotech Undervalued based on future growth
U.S. Pharmaceuticals & Biotech Undervalued based on future growth
Results
12
Companies which can be considered undervalued when accounting for expected future growth (PEG under 0.8)
12 companies
Royalty Pharma
Market Cap: US$31.6b
Operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States.
RPRX
US$54.27
7D
-1.1%
1Y
54.6%
ACADIA Pharmaceuticals
Market Cap: US$3.6b
A biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America.
ACAD
US$21.27
7D
-2.0%
1Y
-4.0%
Organon
Market Cap: US$3.5b
Develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internationally.
OGN
US$13.44
7D
0.4%
1Y
31.9%
Harmony Biosciences Holdings
Market Cap: US$2.0b
A commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare neurological diseases in the United States.
HRMY
US$34.18
7D
0.2%
1Y
5.3%
ADMA Biologics
Market Cap: US$1.9b
A biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally.
ADMA
US$8.50
7D
5.5%
1Y
-58.3%
ANI Pharmaceuticals
Market Cap: US$1.7b
A biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally.
ANIP
US$82.29
7D
1.3%
1Y
29.9%
Collegium Pharmaceutical
Market Cap: US$1.1b
A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.
COLL
US$34.19
7D
2.8%
1Y
15.1%
Zevra Therapeutics
Market Cap: US$747.8m
A commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States.
ZVRA
US$12.55
7D
3.8%
1Y
37.5%
Omeros
Market Cap: US$632.2m
A clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases.
OMER
US$9.33
7D
-5.3%
1Y
176.9%
Abeona Therapeutics
Market Cap: US$315.2m
A commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States.
ABEO
US$5.67
7D
5.4%
1Y
-4.9%
SIGA Technologies
Market Cap: US$309.8m
A commercial-stage pharmaceutical company, focuses on the health security market in the United States.
SIGA
US$4.34
7D
0.2%
1Y
-33.2%
Earth Science Tech
Market Cap: US$52.3m
Together with its subsidies, focuses on health and wellness industry.
ETST
US$0.17
7D
-2.3%
1Y
16.0%